Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Srdan Verstovsek is a medical oncologist and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas. Dr. Verstovsek’s clinical and translational research is focused on understanding the biology of and developing new therapies for myeloproliferative neoplasms (MPNs). He is Director of the Clinical Research Center for MPNs at MD Anderson. He has been principal investigator of more than 50 clinical trials testing novel therapies for patients with MPNs and has published more than 350 peer-reviewed manuscripts. Dr. Verstovsek is actively involved with national patient groups and is a frequently invited speaker on these disorders both nationally and internationally. In 2010, he was awarded the Celgene 2010 Young Investigator Award for Clinical Research in Hematology and in 2011 he was awarded the Distinguished Alumnus Award, Division of Cancer Medicine, MD Anderson. In 2013 Dr. Verstovsek was awarded the 7th Annual Irwin H. Krakoff Award for Excellence in Clinical Research by Division of Cancer Medicine, MD Anderson, and the Distinguished Lecturer Award from the Society of Hematologic Oncology. In 2015 Dr. Verstovsek was elected as a member in recognition of his contributions as a physician-scientist to The American Society for Clinical Investigation. His disclosures include Incyte Corporation, Roche, Astrazeneca, Lilly Oncology, Ns Pharma, Bristol Myers Squibb, Celgene, Gilead, Seattle Genetics, Promedior, CTI BioPharma Corp., Galena BioPharma, Pfizer, Genentech and Blueprint Medicines Corp.